CICC initiated coverage of Novo Nordisk (NVO) with an Outperform rating and $73.50 price target
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NVO:
- Novo Nordisk Expands CagriSema Push Into Youth Diabetes: Early Trial Update for Investors
- Novo Nordisk’s CagriSema Appetite Study Adds Depth to Its Obesity Pipeline
- LLY, JNJ, PFE: Big Pharma’s 2025 Comeback Is Bigger Than the Obesity Craze
- Moderately bullish activity in Novo Nordisk with shares up 0.58%
- Eli Lilly Stock (LLY) Has 50% Upside, Says Citigroup